Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Bristol-Myers Squibb announced the launch of Orencia® (abatacept) ClickJect™ Autoinjector, a new autoinjector for adults with moderate to severe rheumatoid arthritis (RA).
The Orencia® ClickJect™ automatically delivers a 125mg/mL dose subcutaneously with the push of a button and the user holding for 15 seconds. The step-by-step directions help patients with the injection process and its large viewing window with blue indicator help confirm the injection of a full dose. The lightweight device has a non-slip grip design for better control in patients with compromised dexterity. The ClickJect’s™ transparent tip automatically locks and covers the needle post-injection.
The usability and acceptability of the Orencia® ClickJect™ was evaluated in a summative study (n=48) where patients rated comfort (P=0.0157), control (P = .0002), ease of use (P = .021), and confidence of dose (P = .896). Mean scores for the device ranged from 6.4–6.9 on a 7-point scale.
Orencia®, a selective costimulation modulator, is approved to reduce signs/symptoms, induce major clinical response, inhibit progression of structural damage, and improve physical function in patients with moderately-to-severely active RA and may be used alone or with DMARDS other than TNF antagonists.
It is also indicated to reduce signs/symptoms of moderately-to-severely active polyarticular juvenile idiopathic arthritis in patients ≥6 years of age and may be used alone or with methotrexate. Orencia® is now available as a prefilled syringe, Autoinjector, and lyophilized powder for IV infusion.
Reference
Bristol-Myers Squibb Press Office. Bristol-Myers Squibb Announces Availability of FDA-Approved ORENCIA® (abatacept) ClickJect™, a Self-Administered Subcutaneous Autoinjector, for Adults with Moderate to Severe Rheumatoid Arthritis. Published online July 20, 2016. Accessed July 26, 2016.
This article originally appeared on MPR
